Healthcare Industry News: UCERIS
News Release - April 10, 2012
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of DirectorsSAN DIEGO--(Healthcare Sales & Marketing Network)--Santarus, Inc. (NASDAQ: SNTS ) today announced the appointment of Alessandro E. Della Chà and Matthew W. Strobeck, Ph.D., to the company’s board of directors, increasing its board membership to nine.
“We welcome our new board members and look forward to drawing on their industry, business and corporate expertise as we continue to build Santarus into a premier specialty biopharmaceutical company,” said David F. Hale, chairman of the board of Santarus. “Alex also brings us an international perspective and a strong relationship with a key corporate partner. Matt has an impressive background in life sciences and valuable financial experience, including his prior role with Westfield Capital Management.”
Since 1997, Mr. Della Chà has been a senior partner of Studio Legale Edoardo Ricci e Associati, a leading boutique commercial law firm in Milan, Italy, and has served as a co-managing director of the firm since 2003. Mr. Della Chà has represented Italian companies and banks in litigation, commercial and bankruptcy matters, with significant experience in the fields of capital market transactions, IPOs, private placements, corporate governance issues and corporate restructurings. He currently serves as a director of Cosmo Pharmaceuticals S.p.A. Mr. Della Chà holds a degree in law from the Università degli Studi di Milano and a Masters in European commercial law from the University of Leicester, England.
Dr. Strobeck was a partner, member of the management committee and member of the advisory board of Westfield Capital Management from 2008 to 2011. Dr. Strobeck organized and led the purchase of Westfield in 2008 from Boston Private Bank, and prior to this transaction he was a member of the Westfield investment team since 2003. Dr. Strobeck currently serves as a member of the board of directors of Metabolix, Inc. Dr. Strobeck received a B.S. in biology from St. Lawrence University and a Ph.D. in cellular and molecular biology from the University of Cincinnati. In addition, Dr. Strobeck received an S.M. from the Harvard University-MIT Health Sciences Technology Program and an S.M. from the MIT Sloan School of Management.
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company’s current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes, and on FENOGLIDE® (fenofibrate) tablets, which is indicated as an adjunct to diet to reduce high cholesterol.
Santarus has a diverse product development pipeline. A New Drug Application for UCERIS™ (budesonide) tablets for induction of remission of mild to moderate active ulcerative colitis is under review by the FDA with a response expected in October 2012. The pipeline also includes two late-stage investigational drugs: RHUCIN® (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema and rifamycin SV MMX® for treatment of travelers’ diarrhea, both of which are being evaluated in Phase III clinical studies. In addition, the company’s investigational monoclonal antibody, SAN-300, is being evaluated in a Phase I clinical program. More information about Santarus is available at www.santarus.com.
Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarus’ business, including, without limitation: difficulties or delays in development, testing, manufacturing and marketing of, and obtaining and maintaining regulatory approvals for, Santarus’ products; and other risks detailed in Santarus’ prior press releases as well as in public periodic filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Santarus®, FENOGLIDE® and UCERIS™ are trademarks of Santarus, Inc. GLUMETZA® is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc. CYCLOSET® is a trademark of VeroScience LLC. MMX® is a trademark of Cosmo Technologies Limited. RHUCIN® is a trademark of Pharming Group NV.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.